Kala Pharmaceuticals, Inc. (KALA)
USD 3.49
(3.56%)
USD 3.49
(3.56%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -42.19 Million USD | -18823.32% |
| 2022 | -223 Thousand USD | 99.85% |
| 2021 | -152.29 Million USD | -35.97% |
| 2020 | -112 Million USD | -9.83% |
| 2019 | -101.98 Million USD | -52.81% |
| 2018 | -66.73 Million USD | -58.11% |
| 2017 | -42.21 Million USD | -27.27% |
| 2016 | -33.16 Million USD | -98.82% |
| 2015 | -16.68 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -9.57 Million USD | 18.87% |
| 2024 Q1 | -11.8 Million USD | -36.86% |
| 2023 Q4 | -8.62 Million USD | 0.88% |
| 2023 FY | -42.19 Million USD | -18823.32% |
| 2023 Q1 | -18.7 Million USD | -34.93% |
| 2023 Q2 | -10.41 Million USD | 44.32% |
| 2023 Q3 | -8.7 Million USD | 16.41% |
| 2022 Q4 | -13.86 Million USD | -147.67% |
| 2022 FY | -223 Thousand USD | 99.85% |
| 2022 Q2 | -27.26 Million USD | 17.39% |
| 2022 Q3 | 29.07 Million USD | 206.64% |
| 2022 Q1 | -33 Million USD | 30.62% |
| 2021 Q1 | -30.41 Million USD | 2.25% |
| 2021 Q3 | -28.12 Million USD | 22.94% |
| 2021 Q4 | -47.56 Million USD | -69.12% |
| 2021 FY | -152.29 Million USD | -35.97% |
| 2021 Q2 | -36.49 Million USD | -20.01% |
| 2020 FY | -112 Million USD | -9.83% |
| 2020 Q4 | -31.11 Million USD | -11.32% |
| 2020 Q3 | -27.94 Million USD | -19.89% |
| 2020 Q2 | -23.31 Million USD | -6.18% |
| 2020 Q1 | -21.95 Million USD | 0.01% |
| 2019 Q3 | -23.17 Million USD | 2.72% |
| 2019 Q2 | -23.82 Million USD | 6.16% |
| 2019 Q1 | -25.38 Million USD | -0.67% |
| 2019 FY | -101.98 Million USD | -52.81% |
| 2019 Q4 | -21.95 Million USD | 5.26% |
| 2018 Q2 | -14.62 Million USD | -29.41% |
| 2018 Q3 | -15.6 Million USD | -6.72% |
| 2018 FY | -66.73 Million USD | -58.11% |
| 2018 Q1 | -11.29 Million USD | -0.06% |
| 2018 Q4 | -25.21 Million USD | -61.62% |
| 2017 Q4 | -11.29 Million USD | -10.96% |
| 2017 Q1 | -9.75 Million USD | -16.25% |
| 2017 Q2 | -10.98 Million USD | -12.57% |
| 2017 Q3 | -10.17 Million USD | 7.38% |
| 2017 FY | -42.21 Million USD | -27.27% |
| 2016 Q4 | -8.39 Million USD | 13.16% |
| 2016 Q2 | -9.85 Million USD | -87.6% |
| 2016 FY | -33.16 Million USD | -98.82% |
| 2016 Q1 | -5.25 Million USD | 0.0% |
| 2016 Q3 | -9.66 Million USD | 1.89% |
| 2015 FY | -16.68 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 187.632% |
| Embecta Corp. | 70.4 Million USD | 159.942% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 324.714% |
| Dynavax Technologies Corporation | -6.38 Million USD | -560.495% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 79.833% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 200.582% |
| PainReform Ltd. | -9.34 Million USD | -351.616% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -436.201% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -836.498% |
| SCYNEXIS, Inc. | 67.04 Million USD | 162.945% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -1261.903% |
| Cosmos Health Inc. | -18.54 Million USD | -127.578% |
| Journey Medical Corporation | -3.85 Million USD | -995.225% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -836.498% |
| Safety Shot Inc | -15.08 Million USD | -179.778% |
| Alpha Teknova, Inc. | -36.78 Million USD | -14.734% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 69.788% |
| Bright Green Corporation | -13.12 Million USD | -221.451% |
| Procaps Group, S.A. | 42.54 Million USD | 199.198% |
| Theratechnologies Inc. | -23.95 Million USD | -76.145% |
| Harrow Health, Inc. | -24.41 Million USD | -72.869% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -772.782% |
| Biofrontera Inc. | -20.13 Million USD | -109.622% |
| DURECT Corporation | -27.62 Million USD | -52.762% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 3306.611% |
| Cronos Group Inc. | -73.96 Million USD | 42.946% |
| OptiNose, Inc. | -35.48 Million USD | -18.927% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 95.79% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 276.447% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 953.367% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 26802.651% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -572.031% |
| Radius Health, Inc. | -25.79 Million USD | -63.619% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -584.708% |
| ProPhase Labs, Inc. | -16.78 Million USD | -151.454% |
| Phibro Animal Health Corporation | 2.41 Million USD | 1846.647% |
| Procaps Group S.A. | 42.54 Million USD | 199.198% |
| Alvotech | -551.73 Million USD | 92.352% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -310.576% |
| Viatris Inc. | 54.7 Million USD | 177.146% |
| Rockwell Medical, Inc. | -8.43 Million USD | -400.047% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -166.341% |
| SIGA Technologies, Inc. | 68.06 Million USD | 161.995% |
| Tilray Brands, Inc. | -244.98 Million USD | 82.775% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 451.278% |
| Shineco, Inc. | -22.44 Million USD | -87.977% |
| PetIQ, Inc. | 2.13 Million USD | 2080.244% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -880.953% |
| Incannex Healthcare Limited | -18.45 Million USD | -128.609% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 116.9% |
| Alimera Sciences, Inc. | -20.13 Million USD | -109.612% |
| Silver Spike Investment Corp. | 7.34 Million USD | 674.91% |
| Assertio Holdings, Inc. | -331.94 Million USD | 87.287% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -540.085% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -416.943% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | -135.762% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -110.392% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 73.671% |
| Hempacco Co., Inc. | -13.12 Million USD | -221.49% |
| Talphera, Inc. | -18.39 Million USD | -129.38% |
| Alvotech | -551.73 Million USD | 92.352% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 218.397% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 112.918% |
| Currenc Group, Inc. | -15.3 Million USD | -175.692% |
| Kamada Ltd. | 8.28 Million USD | 609.404% |
| Indivior PLC | 2 Million USD | 2209.95% |
| Evoke Pharma, Inc. | -7.79 Million USD | -441.548% |
| Flora Growth Corp. | -57.03 Million USD | 26.013% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -110.392% |
| Evolus, Inc. | -61.68 Million USD | 31.59% |
| HUTCHMED (China) Limited | 100.78 Million USD | 141.872% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 130.68% |
| Akanda Corp. | -32.27 Million USD | -30.748% |